Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke

Phase 3 Recruiting 348 enrolled Second Affiliated Hospital of Guangxi Medical University Ganzhou City People's Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.

Timeline

Start: 2024-04-24
Primary completion: 2025-12-31
Completion: 2026-03-31

Outcome

Met primary endpoint

paper An excellent outcome at 90 days was observed in 113 patients (63.8%) in the tirofiban group and in 95 patients (52.2%) in the placebo group PMID 42100960 ↗

paper risk ratio, 1.22; 95% CI, 1.02-1.46; P = .03 PMID 42100960 ↗

Publications

INSTANT Trial Authors for the INSTANT Investigators; Liu X, Zhang F, Zhang C, Li Z, Yuan G, Kong D, Xie S, Zhou M, Ye J, Lai Z, Li D, Xu H, Chen L, Cheng F, Shi Y, Chen B, Hu W, Liu H, Yin Y, Deng X, Xie Z, Li C, Shi J, Mei D, Liu B, Wang B, Zhou R, Liu J, Shen L, Hu H, Xiao G, Guan X, Yuan S, Lv X, Liang S, Zeng X, Chen Y, Cao W, Zheng C, Liu Y, Li J, Guan B, Lai T, Sun W, Zeng H, Zhang J, Li S, Sang H, Tang Y, Wang D, Lu M, Kaesmacher J, Yogendrakumar V, Pan S, Nogueira RG, Hong D, Goyal M, Thomalla G, Nguyen TN, Saver JL, Yang Q, Qiu Z, Zeng G. Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. JAMA. 2026 Jun 9;335(22):1949-1958. doi: 10.1001/jama.2026.5245.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirofiban	Other / unclassified	0.075 ug/kg	Intravenous